ERBB2 and non-small cell lung carcinoma: Mazieres et al. include 551 patients with driver gene positivity (including KRAS, EGFR, ERBB2, ALK, ROS-1, BRAF, RET) NSCLC, and 94.6% of patients received ICIs monotherapy after TKIs or chemotherapy progression [24].